INmune Bio Inc.
INMB
$2.17
$0.094.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 0.00 | -- | -- |
| SG&A Expenses | 2.28M | 2.17M | 2.92M | 2.68M | 2.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.48M | 5.81M | 5.47M | 7.43M | 8.06M |
| Operating Income | -1.48M | -5.81M | -5.47M | -7.43M | -8.06M |
| Income Before Tax | -1.27M | -5.41M | -5.26M | -6.47M | -24.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.27M | -5.41M | -5.26M | -6.47M | -24.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.27M | -5.41M | -5.26M | -6.47M | -24.46M |
| EBIT | -1.48M | -5.81M | -5.47M | -7.43M | -8.06M |
| EBITDA | -1.41M | -5.76M | -5.42M | -7.42M | -- |
| EPS Basic | -0.05 | -0.20 | -0.20 | -0.24 | -1.05 |
| Normalized Basic EPS | -0.03 | -0.13 | -0.12 | -0.17 | -0.21 |
| EPS Diluted | -0.05 | -0.20 | -0.20 | -0.24 | -1.05 |
| Normalized Diluted EPS | -0.03 | -0.13 | -0.12 | -0.17 | -0.21 |
| Average Basic Shares Outstanding | 26.72M | 26.59M | 26.61M | 26.59M | 23.30M |
| Average Diluted Shares Outstanding | 26.72M | 26.59M | 26.61M | 26.59M | 23.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |